Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)

NCT02354170 is registered in ClinicalTrials.gov with Roger Goldberg, M.D., MBA as lead sponsor.

NCT NCT02354170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02354170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)
Lead sponsor
Roger Goldberg, M.D., MBA
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
April 27, 2017
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

central serous chorioretinopathy